Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of periphe...

Descripción completa

Detalles Bibliográficos
Autores: Hidalgo-Ríos, Samuel, Carrillo García, Jaime|||0000-0002-2861-3015, Moura, David S., Stacchiotti, Silvia|||0000-0002-1742-8666, López Pousa, Antonio, Redondo, Andrés, Italiano, Antoine|||0000-0002-8540-5351, Gutiérrez, Antonio|||0000-0001-9062-077X, Grignani, Giovanni|||0000-0001-5515-569X, Hindi, Nadia|||0000-0002-5864-762X, López-Guerrero, J.A.|||0000-0002-7369-8388, Garcia del Muro, Xavier|||0000-0001-5571-2847, Martínez Trufero, Javier|||0000-0002-0997-2573, Palmerini, Emanuela|||0000-0003-3406-6705, Sebio, Ana|||0000-0003-3333-2370, Bernabeu, Daniel|||0000-0003-0828-9104, Le Cesne, Axel, Casali, Paolo Giovanni|||0000-0003-4056-8023, Blay, Jean-Yves|||0000-0001-7190-120X, Cruz-Jurado, Josefina|||0000-0001-6398-1641, Martín-Broto, Javier|||0000-0001-7350-6916
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:282267
Acceso en línea:https://ddd.uab.cat/record/282267
https://dx.doi.org/urn:doi:10.3390/cancers14174186
Access Level:acceso abierto
Palabra clave:Solitary fibrous tumour
Pazopanib
Inflammation
Neutrophil/lymphocyte ratio
NLR
Platelet/lymphocyte
PLR
Red cell distribution width
RDW
Descripción
Sumario:Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16.8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib.

Similares en LA Referencia